AstraZeneca India Pharma on Thursday said it has received approval from the government authority for the import, sale, and distribution of a medication used in treating non-small cell lung cancer ...

AstraZeneca CEO Pascal Soriot views the company's stock price — up just 10% year-to-date — as a marker of how he is doing. He’d like it to be higher.

AstraZeneca has produced some fresh data to back up its blockbuster ambitions for camizestrant, tying the oral SERD to a 56% improvement in progression-free survival (PFS) in a phase 3 breast ...

Drugmaker AstraZeneca has agreed to pay $50.9 million to settle a class action lawsuit in U.S. court accusing the company of scheming to delay a generic version of its schizophrenia drug Seroquel ...

AstraZeneca’s immunotherapy Imfinzi has proven it can help certain patients with early-stage stomach cancer, according to results from a phase 3 study. Adding Imfinzi to the chemotherapy regimen ...

AstraZeneca welcomed NICE’s decision, which expands access beyond previous eligibility criteria set in 2022. It aligns with a recent acceptance by the Scottish Medicines Consortium (SMC) for the same ...

CHICAGO >> Treating breast cancer patients with AstraZeneca’s experimental pill camizestrant at the first sign of resistance to standard therapies cut the risk of disease progression or death by ...

At ASCO Day 3, AstraZeneca dominates, Takeda reveals experimental drug data, Eli Lilly serves salad. The SERD spectacle, the VERIFY study, and the dream of a better multi-cancer liquid biopsy test.

AstraZeneca Plc (NASDAQ:AZN) on Monday released results from three Phase 3 clinical trials at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting: DESTINY-Breast09, MATTERHORN ...

AstraZeneca's AZN short percent of float has risen 50.0% since its last report. The company recently reported that it has 7.34 million shares sold short , which is 0.24% of all regular shares that ...

AstraZeneca Pharma shares rose nearly 12 per cent after the company posted strong Q4 results. Profit jumped 48 per cent and revenue increased by 25 per cent. Growth came from cancer, heart, and ...